Edition:
United States

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.41USD
21 Nov 2017
Change (% chg)

$0.05 (+3.68%)
Prev Close
$1.36
Open
$1.38
Day's High
$1.45
Day's Low
$1.38
Volume
884,549
Avg. Vol
794,564
52-wk High
$1.77
52-wk Low
$0.73

Summary

Name Age Since Current Position

James Young

64 2011 Independent Chairman of the Board

Stanley Erck

68 2017 President, Chief Executive Officer, Interim Chief Financial Officer, Director

Gregory Glenn

63 2016 President, Research and Development

John Herrmann

52 2014 Senior Vice President, General Counsel, Corporate Secretary

John Trizzino

57 2014 Senior Vice President - Commercial Operations

James Cummings

2017 Vice President - Clinical Development and Translational Medicine

Rajiv Modi

56 2009 Director

Richard Douglas

64 2010 Independent Director

Gary Evans

59 2011 Independent Director

Michael McManus

74 1998 Independent Director

Biographies

Name Description

James Young

Dr. James F. Young, Ph.D., is an Independent Chairman of the Board of Novavax, Inc. He is Chairman of the Board and Chief Executive Officer of Targeted Microwave Solutions, Inc. since 2016. Former President, Research and Development, at MedImmune, Inc. Dr. Young has been Chairman of the Board of Novavax, Inc. since April 2011 and a Director since April 2010. Dr. Young held the position of President, Research and Development, at MedImmune, Inc. from 2000 until 2008 and previously served as Executive Vice President, Research and Development from 1999 to 2000, Senior Vice President from 1995 to 1999, and as Senior Vice President, Research and Development from 1989 to 1995. Dr. Young serves as a member of the boards of Targeted Microwave Solutions, Inc. (TGTMF), CannaRoyalty Corp. (CNNRF), and 3-V Biosciences, Inc., a privately-held biopharmaceutical company developing novel antiviral therapeutics. Dr. Young received B.S. degrees in general science and biology from Villanova University, as well as a Ph.D. in microbiology and immunology from Baylor College of Medicine.

Stanley Erck

Mr. Stanley C. Erck is re-designated as President, Chief Executive Officer, Interim Chief Financial Officer, Director of the Company effective November 10, 2017. He was President, Chief Executive Officer, Director of Novavax, Inc. since April 2011. Former Executive Chairman of Novavax, Inc. from February 2010 until April 2011, and a Director since June 2009. From 2000 to 2008, Mr. Erck served as President, Chief Executive Officer and Director of Iomai Corporation, a vaccine development company, which was acquired in 2008 by Intercell. Prior to that, Mr. Erck previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International. Mr. Erck serves as a member of the boards of BioCryst Pharmaceuticals, Inc. (BCRX), MaxCyte, Inc., and MDBio Foundation. Mr. Erck received a B.S. in economics from the University of Illinois and a M.B.A from the University of Chicago.

Gregory Glenn

Dr. Gregory M. Glenn M.D., is President, Research and Development of Novavax, Inc. Previously served as Senior Vice President, Research and Development since January 2014, as Senior Vice President, Chief Medical Officer from January 2011 to January 2014, and Senior Vice President and Chief Scientific Officer from June 2010 to January 2011. Prior to joining the Company, Dr. Glenn was the Chief Scientific Officer and founder of Iomai Corporation, which was acquired in 2008 by Intercell AG, an associate in international health at Johns Hopkins University’s School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research. Dr. Glenn received a B.A. in biology and chemistry from Whitman College and a M.D. from Oral Roberts University School of Medicine. He also completed the Medical Research Fellowship at the Walter Reed Army Institute of Research.

John Herrmann

Mr. John A. Herrmann, III is the Senior Vice President, General Counsel, Corporate Secretary of the Company. He previously served as the Company’s Vice President, General Counsel and Corporate Secretary from March 2012 to June 2014, and its Executive Director, Legal Affairs and Corporate Secretary from April 2010 to March 2012. Prior to joining the Company, Mr. Herrmann was General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. Mr. Herrmann worked as Senior Counsel for Celera Genomics following his position as Senior Corporate Counsel at Baxter Healthcare in its Renal Division. Mr. Herrmann received a B.A. in political science and history from Brown University and a J.D. from the University of Illinois.

John Trizzino

Mr. John J. Trizzino is Senior Vice President - Commercial Operations of Novavax, Inc. He previously served as the Company’s Senior Vice President, Business Development from August 2010 to September 2011, and its Senior Vice President, International and Government Alliances from July 2009 to July 2010. Prior to joining the Company, Mr. Trizzino was the CEO of Immunovaccine from September 2011 to September 2013, VP, Vaccine Franchise at Medimmune, LLC, Senior Vice President, Business Development at ID Biomedical, and Vice President, Business Development in the Medical Group of Henry Schein, Inc. following his position as Vice President, General Manager of its GIV division. Mr. Trizzino also serves on the board of directors of The Maryland Tech Council. Mr. Trizzino received a B.S. from Long Island University, CW Post and a M.B.A. from New York University.

James Cummings

Dr. James F. Cummings is Vice President - Clinical Development and Translational Medicine of the company. He joined Novavax as Senior Director of Clinical Development in September 2015, with a specific focus on advancing Novavax' programs within emerging infectious disease. Previously, Dr. Cummings served as the Director for Global Emerging Infections Surveillance and Response System (GEIS) at the Armed Forces Health Surveillance Branch (AFHSB), Director, Translational Medicine Branch & Division of Regulated Activities at Walter Reed Army Institute of Research (WRAIR) and Consultant to the U.S. Army Surgeon General for all Medical Research and Development.

Rajiv Modi

Dr. Rajiv I. Modi, Ph.D., is Director of Novavax, Inc., since April 1, 2009. He is Managing Director of Cadila Pharmaceuticals, Ltd. (“Cadila”), a company organized in India, since 1995. Dr. Modi was elected to Novavax, Inc.’s Board based upon his relationship with the Company’s largest stockholder at the time. As of April 19, 2017, Satellite Overseas (Holdings) Limited, a subsidiary of Cadila, holds approximately 0.9% of the Company’s outstanding Common Stock. Dr. Modi serves as a member of the boards of other Cadila group companies. Mr. Modi serves as a member of the boards of Energy Hunter Resources, Inc., Targeted Microwave Solutions, and Cadila Pharmaceuticals, Ltd. Dr. Modi received a bachelor’s degree of technology in chemical engineering from the Indian Institute of Technology, a master’s degree in biological engineering from University College, London, and a Ph.D. in biological science from the University of Michigan.

Richard Douglas

Dr. Richard H. Douglas, Ph.D., is an Independent Director of Novavax, Inc. He is Former Senior Vice President, Corporate Development, Genzyme Corporation. From 1989 to 2011, Dr. Douglas led Genzyme Corporation’s Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Dr. Douglas was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology. Dr. Douglas serves as a member of the boards of University of Michigan Technology Transfer National Advisory Board and Aldeyra Therapeutics, Inc. (ALDX). Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley.

Gary Evans

Mr. Gary C. Evans is an Independent Director of Novavax, Inc. He presently serves as Chairman of the Board and Chief Executive Officer of Energy Hunter Resources, Inc., a Dallas based oil and gas exploration and production company. From May 2009 until May 2016, Mr. Evans served as Chairman of the Board and Chief Executive Officer of Magnum Hunter Resources Corporation (“Magnum Hunter”), a public energy company specializing in unconventional resource plays predominately in the Appalachian Basin. In December 2015, Magnum Hunter filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Mr. Evans was also founder and CEO of Eureka Hunter Holdings, LLC, a mid-stream gas gathering company transporting and managing up to 1 BCF of daily natural gas volumes from production in West Virginia and Ohio on approximately 200 miles of newly constructed pipeline during the similar seven-year period. Additionally, Mr. Evans previously founded and served as the Chairman and Chief Executive Officer of Magnum Hunter Resources Inc. (MHRI), a NYSE listed company, for twenty years before selling MHRI to Cimarex Energy for approximately $2.2 billion in June 2005. Later that year, Mr. Evans formed Wind Hunter Energy, LLC, a renewable energy company which was subsequently acquired in December 2006 by GreenHunter Energy, Inc., an emerging water resource company focusing on oil field water management and clean water technologies active in the Marcellus and Utica resource plays in Appalachia. As founder, Mr. Evans has served as Chairman and Chief Executive Officer of GreenHunter Energy, Inc. since December 2006 until May 2016 upon the sale of its assets to a private equity fund. Mr. Evans was recognized by Ernst and Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy Sector and was subsequently inducted into the World Hall of Fame for Ernst & Young Entrepreneurs. Mr. Evans was also recognized as the Energy Industry

Michael McManus

Mr. Michael A. McManus, Jr., J.D. is an Independent Director of Novavax, Inc. He is Former President and Chief Executive Officer of Misonix, Inc. from 1999 to 2016. Mr. McManus served as President, Chief Executive Officer and Director of New York Bancorp Inc. from 1991 through March 1998. He also served as President and Chief Executive Officer of Home Federal Savings Bank, the principal subsidiary of New York Bancorp Inc., from February 1995 through March 1998. From 1990 through November 1991, Mr. McManus was President and Chief Executive Officer of Jamcor Pharmaceuticals Inc. Mr. McManus served as an Assistant to the President of the United States from 1982 to 1985 and held positions with Pfizer Inc. and Revlon Group. Mr. McManus served in the U.S. Army Infantry from 1968 through 1970. Mr. McManus is a recipient of the Ellis Island Medal of Honor. Mr. McManus received a B.A. in economics from the University of Notre Dame and a J.D. from the Georgetown University Law Center.

Basic Compensation

Name Fiscal Year Total

James Young

424,250

Stanley Erck

3,877,820

Gregory Glenn

1,642,670

John Herrmann

1,132,820

John Trizzino

1,157,200

James Cummings

--

Rajiv Modi

--

Richard Douglas

189,700

Gary Evans

192,200

Michael McManus

202,700
As Of  30 Dec 2016